Anti-fibrotic drugs dealing with pulmonary fibrosis after COVID-19-associated acute respiratory distress syndrome

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus which is responsible for coronavirus disease(COVID-19),uses an angiotensin-2-converting enzyme(ACE2)as a cell receptor in humans.Initially,there is interstitial lung damage after infection,and then parenchymal lesions appear,which if not managed appropriately could worsen.Available data suggests that around 40%of patients with COVID-19 develop acute respiratory distress syndrome(ARDS),and 20%of these patients who develop ARDS require invasive and advanced modes of ventilation[1].